Sponsor

Ipsen

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Ipsen appears in 56 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials56
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

56 shown
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyNCT05759273 · lead sponsor · 2023-04-24
COMPLETED
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateNCT05590793 · lead sponsor · 2022-11-17
COMPLETED
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the ProstateNCT05458856 · lead sponsor · 2022-08-30
COMPLETED
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentNCT05377684 · lead sponsor · 2022-06-09
COMPLETED
Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.NCT04593420 · lead sponsor · 2020-11-30
COMPLETED
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)NCT03773133 · lead sponsor · 2019-05-14
TERMINATED
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast CancerNCT03697551 · lead sponsor · 2018-10-22
TERMINATED
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung CancerNCT03088813 · lead sponsor · 2018-04-25
COMPLETED
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist TherapyNCT03516110 · lead sponsor · 2018-03-09
COMPLETED
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer PatientsNCT03017313 · lead sponsor · 2017-07-13
COMPLETED
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNCT02683941 · lead sponsor · 2017-03-06
TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2NCT02660359 · lead sponsor · 2016-07-08
TERMINATED
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1NCT02660138 · lead sponsor · 2016-03-01
TERMINATED
Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.NCT02630641 · lead sponsor · 2015-10-01
COMPLETED
Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) AnaloguesNCT02542501 · lead sponsor · 2015-07-01
COMPLETED
Quality of Life of Patients With Locally Advanced and Metastatic Prostate CancerNCT02853409 · lead sponsor · 2014-01-01
COMPLETED
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerNCT02057666 · lead sponsor · 2014-01-01
TERMINATED
Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate CancerNCT02238366 · lead sponsor · 2013-11-01
COMPLETED
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyNCT01732549 · lead sponsor · 2013-01-01
TERMINATED
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate CancerNCT01715129 · lead sponsor · 2013-01-01
COMPLETED
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.NCT01753297 · lead sponsor · 2012-12-11
COMPLETED
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentNCT01770353 · lead sponsor · 2012-11-01
COMPLETED
GP Extended Action TriptorelinNCT01673984 · lead sponsor · 2012-08-01
TERMINATED
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateNCT01560858 · lead sponsor · 2012-04-01
COMPLETED
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.NCT01562522 · lead sponsor · 2012-03-01
TERMINATED
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate CancerNCT01374087 · lead sponsor · 2011-11-01
TERMINATED
A Long-term Observational Study Cohort in Patients With Advanced Prostate CancerNCT01383863 · lead sponsor · 2011-10-01
COMPLETED
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer PatientsNCT01313273 · lead sponsor · 2011-06-01
TERMINATED
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple SclerosisNCT01357980 · lead sponsor · 2011-05-01
COMPLETED
Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast CancerNCT01230970 · lead sponsor · 2011-05-01
TERMINATED
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mgNCT01257425 · lead sponsor · 2010-12-01
COMPLETED
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate CancerNCT01020448 · lead sponsor · 2009-11-01
COMPLETED
BN83495 in Prostate CancerNCT00790374 · lead sponsor · 2009-01-01
COMPLETED
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive FunctionsNCT00814346 · lead sponsor · 2008-10-01
COMPLETED
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentNCT00489255 · lead sponsor · 2007-05-01
COMPLETED
BN83495 Phase I in Post-menopausal WomenNCT01840488 · lead sponsor · 2007-04-01
COMPLETED
Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)NCT00444639 · lead sponsor · 2007-02-01
TERMINATED
Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate CancerNCT00415246 · lead sponsor · 2006-11-01
TERMINATED
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's DiseaseNCT00500500 · lead sponsor · 2005-07-01
TERMINATED
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAqNCT00234533 · lead sponsor · 2004-06-01
COMPLETED
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)NCT00080015 · lead sponsor · 2004-03-12
COMPLETED
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisNCT00276341 · lead sponsor · 2003-08-26
COMPLETED
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory ComplaintsNCT00276510 · lead sponsor · 2002-02-01
COMPLETED
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in AlgeriaNCT07484971 · collaborator · 2025-07-21
RECRUITING
Long-term Better Than Short-term ADT With Salvage RTNCT04242017 · collaborator · 2020-07-07
RECRUITING
Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)NCT05255666 · collaborator · 2023-07-31
WITHDRAWN
Retrospective Study to Assess Real-Life Use of The Long Acting GnRH Agonist as Prostate Cancer TreatmentNCT06217770 · collaborator · 2023-04-01
COMPLETED
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRTNCT04624828 · collaborator · 2020-10-19
ACTIVE_NOT_RECRUITING
Phase II Study With Cabozantinib in Patients With RET Positive NSCLCNCT04131543 · collaborator · 2019-08-07
UNKNOWN
CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITYNCT04673240 · collaborator · 2019-03-29
UNKNOWN
" Treating MS Patients With Lower Extremity Spasticity Using Dysport"NCT03585569 · collaborator · 2018-05-01
UNKNOWN
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate CancerNCT01957436 · collaborator · 2013-11-13
ACTIVE_NOT_RECRUITING
A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer GrowthNCT01662726 · collaborator · 2012-08-01
TERMINATED
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate CancerNCT01214291 · collaborator · 2011-03-01
WITHDRAWN
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate CancerNCT00667069 · collaborator · 2008-04-07
COMPLETED
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast CancerNCT00630695 · collaborator · 2008-03-01
COMPLETED

Drugs studied in this sponsor's trials

15 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Ipsen as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo8
triptorelin3
abiraterone acetate1
botulinum toxin type A Injection1
cabozantinib 20 MG1
cabozantinib 40 MG1
cabozantinib 60 MG1
docetaxel1
placebo RxCUI 8375 · Lead sponsor in 8 linked trial(s) · 0 currently recruiting 8 trials triptorelin RxCUI 38782 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 3 trials abiraterone acetate RxCUI 1100071 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial botulinum toxin type A Injection RxCUI 1732153 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cabozantinib 20 MG RxCUI 1363269 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cabozantinib 40 MG RxCUI 1790168 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cabozantinib 60 MG RxCUI 1790172 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ferumoxytol RxCUI 473387 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pembrolizumab RxCUI 1547545 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial somatropin RxCUI 61148 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial topotecan RxCUI 57308 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial toremifene RxCUI 38409 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial triptorelin 11.25 MG RxCUI 1863380 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial triptorelin 22.5 MG RxCUI 1863376 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor43
collaborator13
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.